Einzeltreffer — DigiBib

Telomere dysfunction has been identified as a biological marker of cancer progression in several types of cancer, including Head and Neck Squamous Cell Carcinoma (HNSCC). This study aimed to characterize the telomere maintenance genes (TMG)-related signature in prognosis and treatment response in HNSCC. The transcriptome and clinical data of HNSCC were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases, respectively. Non-negative matrix factorization (NMF) was used to identify molecular subtypes derived from TMG. Gene set enrichment analysis (GSEA) was performed to analyze the differentially expressed pathways between subtypes, and a risk score model derived from TMG was established. Kaplan-Meier survival analysis was used to evaluate inter-group prognostic features, and the correlation between TMG-derived molecular subtypes and risk score model with immune infiltration, immunotherapy, and chemosensitivity was assessed. Two HNSCC subtypes were identified based on 59 TMG-related genes, which exhibit significant heterogeneity in prognosis, immune cell infiltration, and treatment response. Additionally, a TMG-derived risk signature containing 9 genes was developed to assess the prognosis of HNSCC patients. The signature had significant predictive ability for HNSCC prognosis and was significantly correlated with immune cell infiltration and immunotherapy response. A nomogram integrating the risk signature, N stage and radiotherapy was constructed to predict 1-, 3-, and 5-year overall survival (OS) of HNSCC patients, which had better performance than other prognostic models and included TMG-derived risk score, radiotherapy, and N stage. This study identified TMG-derived molecular subtypes in HNSCC and developed a novel prognostic score model, highlighting the potential value of TMG in HNSCC prognosis and immunotherapy.

Competing Interests: The authors have no funding and conflicts of interest to disclose.

Titel:	Telomere maintenance genes-derived prognosis signature characterizes immune landscape and predicts prognosis of head and neck squamous cell carcinoma.
Autor/in / Beteiligte Person:	Zou, J ; Chu, S ; Bao, Q ; Zhang, Y
Link:	Zum Volltext
Zeitschrift:	Medicine, Jg. 102 (2023-08-04), Heft 31, S. e34586
Veröffentlichung:	Hagerstown, Md : Lippincott Williams & Wilkins, 2023
Medientyp:	academicJournal
ISSN:	1536-5964 (electronic)
DOI:	10.1097/MD.0000000000034586
Schlagwort:	Humans Squamous Cell Carcinoma of Head and Neck genetics Prognosis Immunotherapy Nomograms Head and Neck Neoplasms genetics Head and Neck Neoplasms therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Medicine (Baltimore)] 2023 Aug 04; Vol. 102 (31), pp. e34586. MeSH Terms: Nomograms* ; Head and Neck Neoplasms* / genetics ; Head and Neck Neoplasms* / therapy ; Humans ; Squamous Cell Carcinoma of Head and Neck / genetics ; Prognosis ; Immunotherapy References: Front Genet. 2022 Nov 04;13:1010044. (PMID: 36406133) ; Front Med (Lausanne). 2023 Mar 09;10:1132676. (PMID: 36968845) ; In Vivo. 2021 Mar-Apr;35(2):753-759. (PMID: 33622868) ; Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) ; BMC Bioinformatics. 2010 Jul 02;11:367. (PMID: 20598126) ; Medicine (Baltimore). 2015 Jul;94(27):e1114. (PMID: 26166107) ; Anticancer Agents Med Chem. 2021 Dec 30;22(2):215-222. (PMID: 34102991) ; Mutat Res. 1996 Jun;340(2-3):67-79. (PMID: 8692183) ; Anal Chem. 2022 Aug 16;94(32):11248-11254. (PMID: 35924299) ; Front Oncol. 2022 Jun 16;12:890154. (PMID: 35785187) ; Cell Res. 2022 Dec;32(12):1086-1104. (PMID: 36280710) ; Mass Spectrom Rev. 2020 Mar;39(1-2):55-82. (PMID: 29889312) ; Front Immunol. 2022 Sep 16;13:975057. (PMID: 36189312) ; Mol Cancer. 2022 Apr 27;21(1):106. (PMID: 35477569) ; Front Immunol. 2023 Mar 10;14:1091218. (PMID: 36969232) ; Cancer Cell. 2018 Aug 13;34(2):315-330.e7. (PMID: 30033091) ; Exp Cell Res. 2022 Jul 15;416(2):113139. (PMID: 35390315) ; Biochem Biophys Res Commun. 2019 Jan 22;508(4):1133-1138. (PMID: 30554657) ; Front Immunol. 2021 Mar 24;12:613530. (PMID: 33841396) ; Front Immunol. 2022 Oct 03;13:1018685. (PMID: 36263048) ; Precis Clin Med. 2019 Sep;2(3):152-165. (PMID: 31598386) ; J Biochem Mol Toxicol. 2017 Dec;31(12):. (PMID: 28914995) ; OMICS. 2012 May;16(5):284-7. (PMID: 22455463) ; Nat Rev Cancer. 2022 Sep;22(9):515-532. (PMID: 35790854) ; Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):3-10. (PMID: 27677729) ; Front Genet. 2022 Aug 26;13:984273. (PMID: 36092898) ; Front Immunol. 2022 Dec 01;13:1025330. (PMID: 36532083) ; J Cancer. 2021 Feb 22;12(8):2165-2172. (PMID: 33758594) ; Int J Gen Med. 2021 Aug 06;14:4219-4227. (PMID: 34393501) ; Nat Med. 2018 Oct;24(10):1550-1558. (PMID: 30127393) ; Cancer Manag Res. 2020 Mar 06;12:1669-1679. (PMID: 32184670) ; Front Immunol. 2022 Oct 28;13:1022808. (PMID: 36389666) ; Nucleic Acids Res. 2021 Jan 8;49(D1):D1420-D1430. (PMID: 33179754) ; Nat Cell Biol. 2022 Feb;24(2):135-147. (PMID: 35165420) ; Cell. 2018 Oct 4;175(2):442-457.e23. (PMID: 30290143) ; Mol Cancer Res. 2023 Jul 5;21(7):648-663. (PMID: 36961398) ; Ther Clin Risk Manag. 2018 Feb 19;14:295-303. (PMID: 29497306) ; Methods Mol Biol. 2018;1711:243-259. (PMID: 29344893) ; Front Oncol. 2019 Oct 09;9:1035. (PMID: 31649890) ; Cancer Res. 2017 Jan 15;77(2):579-589. (PMID: 27671677) ; PLoS Pathog. 2020 Jul 7;16(7):e1008622. (PMID: 32634175) ; Biochem Biophys Res Commun. 2018 Sep 18;503(4):2293-2300. (PMID: 29964012) ; J Cell Physiol. 2020 Nov;235(11):7780-7790. (PMID: 31774184) ; Onco Targets Ther. 2019 Aug 19;12:6639-6651. (PMID: 31695405) ; Oncol Lett. 2021 Dec;22(6):834. (PMID: 34712358) Entry Date(s): Date Created: 20230806 Date Completed: 20230807 Latest Revision: 20230808 Update Code: 20231215 PubMed Central ID: PMC10402981

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Telomere maintenance genes-derived prognosis signature characterizes immune landscape and predicts prognosis of head and neck squamous cell carcinoma.